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Abstract
Cell microparticles (MPs) released in the extracellular milieu can embark plasma membrane and intracellular components
which are specific of their cellular origin, and transfer them to target cells. The MP-mediated, cell-to-cell transfer of three
human membrane glycoproteins of different degrees of complexity was investigated in the present study, using a CHO cell
model system. We first tested the delivery of CAR and CD46, two monospanins which act as adenovirus receptors, to target
CHO cells. CHO cells lack CAR and CD46, high affinity receptors for human adenovirus serotype 5 (HAdV5), and serotype 35
(HAdV35), respectively. We found that MPs derived from CHO cells (MP-donor cells) constitutively expressing CAR (MP-CAR)
or CD46 (MP-CD46) were able to transfer CAR and CD46 to target CHO cells, and conferred selective permissiveness to
HAdV5 and HAdV35. In addition, target CHO cells incubated with MP-CD46 acquired the CD46-associated function in
complement regulation. We also explored the MP-mediated delivery of a dodecaspanin membrane glycoprotein, the CFTR
to target CHO cells. CFTR functions as a chloride channel in human cells and is implicated in the genetic disease cystic
fibrosis. Target CHO cells incubated with MPs produced by CHO cells constitutively expressing GFP-tagged CFTR (MP-GFP-
CFTR) were found to gain a new cellular function, the chloride channel activity associated to CFTR. Time-course analysis of
the appearance of GFP-CFTR in target cells suggested that MPs could achieve the delivery of CFTR to target cells via two
mechanisms: the transfer of mature, membrane-inserted CFTR glycoprotein, and the transfer of CFTR-encoding mRNA.
These results confirmed that cell-derived MPs represent a new class of promising therapeutic vehicles for the delivery of
bioactive macromolecules, proteins or mRNAs, the latter exerting the desired therapeutic effect in target cells via de novo
synthesis of their encoded proteins.
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Introduction
The extracellular milieu contains a vast family of cell-derived,
particulate elements which are heterogenous in size, depending
upon the shedding process, cell type and cellular compartments
from which they are issued. According to the most recent and
generally accepted definition, extracellular microparticles (MPs)
are membrane-derived vesicles with diameter ranging from 100 to
500 nm, which are released from virtually all cell types (reviewed
in [1–5]). Extracellular release of MPs occurs in response to certain
stress conditions [6,7] or pathological processes [8–10]. However,
MPs have also been shown to be released spontaneously and
physiologically, and are now considered as key elements in the cell-
to-cell communications [3,11–13]. This include angiogenesis [14],
blood coagulation [15,16], infection by HIV-1 [17] and other
viruses [4], carcinogenesis [18], inflammation [19], vaccinology
[20], and more generally in immunity [8,21–23]. One particular
case of MP contribution to immunological processes has been
termed ‘trogocytosis‘ [24,25].
In general, MPs carry with them membrane and cytosolic
components specific of their cellular origin [26], including proteins
and nucleic acids, such as mRNAs and microRNAs [7,11,27–30],
and are capable of transferring their cargo to recipient cells
[16,29,31–34]. During their extracellular release, MPs can also
embark components which are foreign to the cells, such as nucleic
acids, proteins or glycoproteins expressed transiently or constitu-
tively by a plasmid or viral vector. The latter scenario is
reminiscent of the process of virus or virus-like particles (VLPs)
pseudotyping by foreign glycoproteins [35–40]. MPs are not only
considered as circulating biomarkers for the molecular profiling of
certain cancers [41], but their therapeutic potential as conveyors of
bioactive factors, proteins, RNAs including miRNAs, is being
evaluated for personalized medicine and for the treatment of a
number of diseases and cellular dysfunctions [5,7,9,11,27,30,42].
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In the present study, we developed a cellular model using
Chinese hamster ovarian cells (CHO) to analyse the MP-mediated
transfer of three human transmembrane glycoproteins with
different degrees of structural complexity and cellular topology,
CAR, CD46 and CFTR. CAR (coxsackie-adenovirus receptor)
and CD46 (complement regulatory protein and pathogen recep-
tor) are well-characterized type I membrane receptors of the Ig-
like family of molecules, which carry a single transmembrane
domain (monospanins). Both CAR and CD46 can act as cell
receptors for different viruses. CAR has been identified as the cell
receptor for the human adenovirus serotype 5 (HAdV5), and other
members of species A, C, D, E and F [43–46]. CD46 acts as a
cellular receptor for several viral pathogens, including measles
virus [47] and members of human adenovirus species B1, B2
(among them HAdV35) and D [43,48,49], and also plays the role
of cofactor in the inactivation of complement components C3b
and C4b by serum factor I [50]. CD46 and CAR differ in their
cellular localization: CD46 is localized at the apical membrane of
epithelial cells [48,50,51], whereas CAR is localized at the tight
junctions [52]. The CFTR (cystic fibrosis transmembrane
conductance regulator) is a complex type III membrane glyco-
protein, with large intracytoplasmic N- and C-terminal domains
and twelve membrane-spanning domains constituting a trans-
membrane, cAMP-dependent chloride channel [53–57]. It is
mainly present at the cellular apical surface of epithelial cells
[58,59], and localised in microdomains of the plasma membrane
referred to as lipid rafts [60].
CHO cells have been shown to efficiently release MPs, even in
the absence of stressing factors [17]. CHO cells were used to
establish stable cell lines which constitutively express CAR, CD46
and CFTR (MP-donor cells). MPs derived from these cells were
first tested for their capacity to incorporate CAR, CD46 or CFTR
(MP packaging or pseudotyping), and secondly, for their compe-
tency in transferring the CAR, CD46, and CFTR proteins and
their specific functions to naive CHO cells used as target cells (MP-
recipient cells). We found that new biological functions associated
to CAR, CD46 or CFTR were acquired by the target CHO cells
after incubation with MP-CAR, MP-CD46 or MP-CFTR,
respectively. Our results demonstrated that MPs have the
therapeutic potential for the cell-to-cell transfer of bioactive
molecules. The function(s) carried over by MPs could be direct, via
MP-packaged therapeutic proteins, or indirect, via specific
mRNAs, such as the mRNA encoding the wild-type CFTR for
the correction of the defective chloride channel function in cystic
fibrosis.
Results
Isolation and Recovery of MPs from CAR- and CD46-
expressing CHO Cells
The CHO-CAR and CHO-CD46 cells were derived from the
parental CHO-K1 cell line to constitutively express and display
CAR [44] and CD46 [61–63] at their surface, respectively. The
recovery of MPs from stressed cells is usually higher than from
nonstressed cells. However, since MPs issued from stressed cells
could transfer stress signals and induce the apoptosis of recipient
cells, our starting material was the culture medium of nonstressed
CHO-CAR and CHO-CD46 cells. Extracellular MPs were
recovered by a two-step ultracentrifugation procedure which
separated MPs according to their size, consisting of a first
sedimentation at 30,0006g, followed by a second at 100,0006g.
Two populations were thus obtained, abbreviated MP30 and
MP100, respectively (Fig. S1). The MP30 fraction contained large
MPs characterized by their heterogeneity in shape and size,
ranging from 50–500 nm in diameter, consistent with plasma
membrane-shedded MPs (Fig. 1A). On the other hand, the MP100
population consisted of homogenous and regular particles, rather
spherical and relatively small in size (50–100 nm; Fig. 1B),
reminiscent of exosomes or exosome-like particles [2,28]. Anti-
bodies directed against human and mouse TSG101 and CD63,
two surface markers of exosomes, were used in attempts to further
characterize this population. However, no clear reaction was
obtained with these antibodies on CHO cell lysates or MP pellets
by Western blot or flow cytometry, respectively. Extracellular MPs
released by CHO-CAR and CHO-CD46 cells were therefore
differentiated only by their sedimentation properties, and referred
to as MP30 and MP100 in the present study.
The yields of MPs spontaneously recovered from 107 cells
(CHO-CAR or CHO-CD46) ranged from 16107 to 36107 for
MP30 after 72 h culture, and a similar recovery was obtained for
MP100. After resuspension of the MP pellets in PBS, the total MP
concentration (titer in physical MPs) of our working stocks usually
ranged between 46107 to 76107 MPs/ml for MP30 or MP100,
corresponding to total protein concentrations in the range of 700–
850 ng/ml. Considering their size and composition heterogeneity,
an average of 100 ng protein corresponded to a total number of
56106 to 76106 MP30 or MP100.
Figure 1. Electron microscopy (EM) of MPs isolated from CHO-
CD46 cells. (A), Negative staining and immuno-EM of MP30CD46. (B),
Negative staining (a), and immuno-EM (b) of MP100CD46. In (A) and (B,
b), immunogold labeling was performed using anti-C46 antibody and
10 nm-gold tagged complementary antibody. MP-associated gold
grains are indicated by arrows. (C), Ultrathin sections of pelletable
complexes of MP30CD46-HAdV5F35, shown at low (a) and high (b)
magnifications. Particles of HAdV5F35 vector (70–80 nm in diameter) in
complex with MP30CD46 are indicated by the letter V.
doi:10.1371/journal.pone.0052326.g001
Microparticles as Vehicles of CAR, CD46 and CFTR
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Efficiency of Incorporation of CAR and CD46 by MPs
MPs isolated from CHO-CAR and CHO-CD46 cells by our
two-step ultracentrifugation procedure were referred to as
MP30CAR and MP100CAR, and MP30CD46 and MP100CD46,
respectively. The proportion of CAR-positive and CD46-positive
MPs was determined by flow cytometry using specific antibodies,
as this technique detected the CAR and CD46 molecules exposed
at the MP surface, and potentially active as adenoviral receptors.
The mean value of the percentage of MP30CAR to total MPs was
5.861.4% (mean 6 SEM, n= 3), corresponding to a mean
bioactive MP titer of 26105 MP30CAR/ml, and only 2.861.2%
for MP100CAR. On the other hand, the mean percentage of
MP30CD46 to total MPs was 7.561.5% (viz. a mean bioactive MP
titer of 56105 MP30CD46/ml), versus 2.261.3% for MP100CD46.
Due to the higher proportion of MPs positive for CAR and CD46
glycoproteins in the MP30 populations, MP30CAR and
MP30CD46 were used for the MP-mediated protein transfer
experiments. By taking into account the value of the bioactivity
titer of our MP30 stocks, the MP dose per target CHO cell ranged
from 5 to 50 MP30CAR or MP30CD46.
The presence of CAR or CD46 molecules at the surface of
MP30 and MP100 was confirmed by immunoelectron microscopy
(immuno-EM), using anti-CAR or anti-CD46 mouse monoclonal
antibody followed by a secondary 10 nm-gold-labeled anti-mouse
IgG. The proportion of MP30 or MP100 associated with anti-
CD46-bound or anti-CAR-bound colloidal gold grains was found
to range between 2 to 3% (Fig. 1A, B). This value was consistent
with the flow cytometry data, considering that MP30 and MP100
adsorbed on a solid support did not offer a full access to antibodies,
compared to MPs in suspension.
CD46 and CAR Molecules Displayed on MP30 were
Functional as Adenoviral Receptors
To assess the functionality of CAR and CD46 molecules on
MP30 as adenoviral receptors, samples of MP30CAR and
MP30CD46 were incubated with HAdV5-GFP or HAdV5F35-
GFP vectors for 2 h at 37uC, using equal numbers of MPs and
vector particles. The samples were then layered over a 20%-
sucrose cushion, and centrifuged at 30,0006g for 2 h. The
material which pelleted through the cushion was fixed and
embedded, and ultrathin sections were processed for observation
under the electron microscope (EM). Numerous complexes of
MP30-viral vector particles were observed in the 30,0006g-
pelletable fraction, as exemplified with MP30CD46 and
HAdV5F35-GFP (Fig. 1C). These results confirmed that CD46
and CAR molecules displayed on MP30 were functional as cellular
receptors for their specific adenoviruses. MP30CHO from
unmodified, parental CHO cells were used as negative control.
MP30CHO and MP30CD46 were incubated with aliquots of
HAdV5F35-GFP vector, as above, and the mixtures added to
monolayers of target CHO cells. Samples were harvested after 2 h
at 37uC, and processed for EM. Particles of adenoviral vector were
observed in complex with MP30CD46 at the surface of the target
cells (Fig. 2A), whereas no vector particle in association with
control MP30CHO was observed (Fig. 2B).
MP-mediated Transfer of CAR and CD46 to Target Cells
(i) Transfer efficiency. To evaluate this parameter, aliquots
of MP30CAR and MP30CD46 were added to CHO cell
monolayers (105 cells per well; 5 MP30/cell), and incubated for
2 h at 37uC. The supernatant was then removed and replaced by
prewarmed complete medium. The cells were further incubated at
37uC, and cell samples were harvested at different time intervals,
from 6 h to 10 days. The presence of CAR and CD46 molecules
on the surface of recipient cells was determined by flow cytometry.
The percentage of CAR- or CD46-positive cells was found to be
approximately 3% at 6 h posttransfer (pt), 6–7% at 24–48 h, and
15–18% after 72 h. The plateau at about 15–18% was maintained
until day-5, and progressively declined after one week (not shown).
(ii) Functionality of CAR and CD46 in MP-recipient cells
(MP dose-dependence). To determine whether CAR and
CD46 were functional as adenoviral receptors in MP-transduced
cells, CHO cells were incubated with increasing doses of
MP30CAR or MP30CD46, ranging from 0 to 30 MP30/cell, and
assayed at 48 h pt for their permissiveness to HAdV5-GFP and
HAdV5F35-GFP, respectively. HAdV5-GFP and HAdV5F35-
GFP were used at a constant MOI of 500 vp/cell. As negative
control, MP30CHO from parental CHO cells were used at the
same doses. With MP30CHO, or at low doses of MP30CAR and
MP30CD46 (#5 MP30/cell), 2 to 10% cells were found to become
GFP-positive (Fig. 3), which corresponded to the background of
infection of CHO cells by HAdV5 and HAdV5F35 via other cell
surface molecules, such as heparan sulfate glucosaminoglycans,
which act as alternative receptors for HAdV5 and HAdV5F35
[43,64]. However, CHO cells pre-incubated with MP30CAR or
MP30CD46, and infected with HAdV5-GFP and HAdV5F35-
GFP, respectively, showed a 2- to 3-fold increase in GFP-positive
cells. This significant increase in permissiveness to the adenovirus
Figure 2. EM of target cells incubated with control MP30CHO or
MP30CD46 in complex with HAdV5F35. (A), Ultrathin sections of
target CHO cells incubated with MP30CD46-HAdV5F35 complexes. V,
particles of HAdV5F35 vector. (B), Ultrathin sections of target CHO cells
incubated with control MP30CHO from nontransduced CHO cells, mixed
with HAdV5F35. Sections are shown at low (a) and high (b)
magnifications. Note the absence of vector particles associated with
control MP30CHO.
doi:10.1371/journal.pone.0052326.g002
Microparticles as Vehicles of CAR, CD46 and CFTR
PLOS ONE | www.plosone.org 3 December 2012 | Volume 7 | Issue 12 | e52326
vectors was MP dose-dependent (Fig. 3). These results indicated
that MP30CAR and MP30CD46 were capable of transfering the
CAR and CD46 molecules to CHO target cells.
(iii) Receptor specificity in MP-recipient cells. As addi-
tional controls, we assessed the specificity of vector-receptor
recognition, by infecting MP30CD46-transduced cells with
HAdV5-GFP, and vice versa, MP30CAR-transduced cells with
HAdV5F35-GFP. Only a background GFP signal was detected
with these two heterotypic pairs, demonstrating the specificity of
the newly acquired CAR and CD46 receptor molecules towards
their respective adenoviral vectors (Fig. 3).
(iv) Functionality of CD46 as complement regulatory
factor in MP-recipient cells. The antiapoptotic activity of
CD46 transferred to CHO cells was analyzed in CHO cells
interacted with MP30CHO or with MP30CD46, then incubated
with increased doses of complement fraction C3. A significant
effect of protection against complement lysis was observed in
MP30CD46-transduced CHO cells, by comparison to control cells
(Fig. 4A).
Influence of VSV-G Incorporation on MP30-mediated
Transfer of CAR or CD46
The following experiments were designed to determine whether
the transfer of CAR or/and CD46 to target CHO cells would be
improved by the incorporation of VSV-G, the envelope glycopro-
tein G of vesicular stomatitis virus, into the MP envelope. We
found that baculovector-mediated expression of VSV-G in CHO-
CAR and CHO-CD46 cells did not enhance the production of
CAR- or CD46-pseudotyped MPs (data not shown). Likewise,
coincorporation of VSV-G with CAR or CD46 into MP30 did not
significantly increase the degree of permissiveness of CHO cells to
HAdV5-GFP or HAdV5F35-GFP after transduction by
MP30CAR-VSV-G or MP30CD46-VSV-G (Fig. S2). This implied
Figure 3. MP30-mediated transfer and functionality of (a) CAR, or (b) CD46 as adenoviral receptors in target cells. Aliquots of CHO cells
(target cells) were incubated with MP30CAR (a) or MP30CD46 (b) at different MP doses per cell, as indicated in the x-axis. At 72 h after MP30-cell
interaction, cells were infected with HAdV5-GFP or HAdV5F35-GFP vector, at the same MOI (500 vp/cell). The degree of CHO permissiveness to
HAdV5-GFP or HAdV5F35-GFP vector was evaluated by flow cytometry analysis of the intracellular GFP signal. In (a), HAdV5F35-GFP, which does not
recognize CAR as cellular receptor, was used as the negative control. In (b), HAdV5-GFP, which does not recognize CD46 as cellular receptor, was
used as the negative control. MP30 from nontransduced CHO cells (Control MP) served as the negative controls in both panels.
doi:10.1371/journal.pone.0052326.g003
Microparticles as Vehicles of CAR, CD46 and CFTR
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that VSV-G was not a facilitator of MP30 uptake by the target
CHO cells, and VSV-G was not included in the following
experiments.
Time-course Analysis of the Acquisition of New
Functionality by MP30-recipient Cells
The next issue was to determine at which time after
MP30CD46-cell interaction the CHO target cells acquired the
adenovirus receptor function carried by CD46. CHO cells were
incubated with a constant dose of MP30CD46 (20 MP30/cell), and
at different times after MP30-cell interaction, the cells were
incubated with HAdV5F35-GFP vector at constant vector MOI
(500 vp/cell) for 2 h at 37uC. At 48 h post-infection (pi), the
permissiveness of the cells to HAdV5F35-GFP was determined by
flow cytometry analysis. A progressive increase in adenoviral
permissiveness was observed, with 10% GFP-positive cells at 48 h
pi, reaching a plateau of 20–25% GFP-positive cells at 72–144 h
(Fig. 4B). Similar results were obtained with MP30CAR (not
shown). The kinetic data implied that a larger proportion of cells
became permissive to adenovirus with time, and suggested the
contribution of additional CD46 molecules. This was likely due to
newly synthesized CD46 from CD46-encoding mRNA transferred
by MP30CD46 to the target cells, as demonstrated below for MP-
mediated CFTR transfer.
Generation of CHO Cells Stably Expressing GFP-CFTR
A CHO cell line stably expressing GFP-fused human CFTR
was generated (CHO-GFP-CFTR) using the pCEP4-GFP-CFTR
episomal plasmid. The pCEP4-GFP-CFTR-directed expression of
the GFP-CFTR fusion protein in these cells showed localisation of
GFP signal in the cytoplasm, perinuclear and submembrane
regions (Fig. 5A i, ii; and Fig. S3A). A similar fluorescence
pattern was observed in CHO-CD46 cells transduced by the
HAdV5F35-GFP-CFTR vector which were used as positive
control (Fig. 5A iii, iv). In CHO-GFP-CFTR cells, the CFTR
molecules were correctly oriented in the plasma membrane, as
Figure 4. Functionality of exogenous CD46 in MP30CD46-transduced CHO cells. (A), CD46 as complement C3 regulator. CHO cells
were harvested at 48 h posttransfer, and the CD46-induced protection against complement C3-mediated cell apoptosis was assayed by the
percentage of Annexin V-positive cells determined by flow cytometry at increasing doses of complement C3. (B), Kinetics of the gain of
adenoviral receptor function by MP30CD46-transduced CHO cells. CHO cells were harvested at different times after MP30CD46-transfer, and
cell permissiveness to the HAdV5F35-GFP vector was assessed by infection with HAdV5F35-GFP at MOI 500. Cells were analyzed for GFP signal at 48 h
postinfection. The degree of permissiveness to the vector was expressed as the percentage of GFP-positive cells (left y-axis), and the relative
transduction efficiency (RTE; right y-axis). The RTE, in arbitrary units (AU), was given using the formula = (percentage of GFP-positive cells) x (MFI;
mean fluorescence intensity).
doi:10.1371/journal.pone.0052326.g004
Microparticles as Vehicles of CAR, CD46 and CFTR
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shown by the labeling of nonpermeabilized CHO-GFP-CFTR
cells with an anti-CFTR monoclonal antibody directed against the
first extracellular loop of the CFTR ectodomain (Fig. 5B).
The chloride channel function in CHO-GFP-CFTR cells was
investigated using the voltage-sensitive probe DiSBAC2(3). The
fluorescent signal of DiSBAC2(3) has been shown to vary with
changes of the membrane potential induced by the cAMP/low-
chloride-mediated activation of the CFTR [65]. Parental CHO
cells were used as negative controls, and CHO-CD46 cells
transduced by the HAdV5F35-GFP-CFTR vector were used as
positive controls. A positive fluorescent signal was observed in
CHO-GFP-CFTR cells in response to the addition of the cAMP-
based cocktail of CFTR activators, demonstrating the functionality
of the exogenous GFP-CFTR molecules as chloride channels
(Fig. 5C). HAdV5F35-GFP-CFTR-transduced cells used as
positive control showed a strong enhancement of the fluorescent
signal in the presence of CFTR activators (Fig. 5C), consistent
with the high transduction efficiency of CHO-CD46 by
HAdV5F35 [55,66]. CHO-GFP-CFTR cells were then tested
for the production of MPs carrying GFP-CFTR (MP-GFP-CFTR)
and the MP-mediated delivery of CFTR to target cells.
Isolation and Recovery of MP-GFP-CFTR
MP30GFP-CFTR and MP100GFP-CFTR were recovered from
the CHO-GFP-CFTR cell culture medium by the ultracentrifu-
gation procedure mentioned above and depicted in Fig. S1. The
presence of the GFP-tag allowed the direct tracking of GFP-CFTR
molecules in the different cell compartments, such as the vesicular
compartment and plasma membrane [55,66]. It also allowed the
detection of GFP-CFTR incorporated in MPs derived from GFP-
CFTR-expressing cells. The recovery of MP30GFP-CFTR and
MP100GFP-CFTR ranged from 1610
7 to 56107 per 107 CHO-
GFP-CFTR cells. Flow cytometry analysis indicated that the GFP-
CFTR signal was detected in both MP30 and MP100 populations,
although in significantly higher amounts in MP30 compared to
MP100 : 10.363.3% GFP-CFTR-positive MP30 (m6 SEM, n= 3),
versus 3.663.3% for MP100. The presence of CFTR in both MP
populations was not surprising, considering the trafficking of
Figure 5. Expression, immunoreactivity and functionality of GFP-CFTR protein expressed from an episomal plasmid in CHO cells
(MP-producer cells). (A), CHO cells harboring the GFP-CFTR-encoding pCEP4 episomal plasmid, were examined by phase-contrast (i) and
epifluorescence microscopy (ii) of GFP-tagged CFTR protein. Positive controls, consisting of CHO cells transduced by the adenoviral vector HAdV5-
GFP-CFTR were similarly examined by phase-contrast (iii) and epifluorescence microscopy (iv). Scale bars, 20 mm. (B), Surface expression and correct
orientation of the GFP-tagged CFTR protein in pCEP4-GFP-CFTR harboring CHO cells, evaluated by flow cytometry using monoclonal antibody
against the first extracellular loop of the CFTR ectodomain. (C), Chloride channel activity of CFTR in negative control CHO cells (dotted bars), positive
control HAdV5F35-GFP-CFTR-transduced CHO-CD46 cells (hatched bars), and pCEP4-GFP-CFTR harboring CHO cells (black bars), evaluated using the
fluorescent probe DiSBAC2(3). The time-course analysis of DiSBAC2(3) fluorescence changes in the presence of a cocktail of CFTR activators was
monitored in regions of the cell monolayers corresponding to 20–30 cells. Bars represent the mean fluorescence value for each field of 20–30 cells 6
SEM. Symbols: *, p,0.05; **, p,0.01; ns, not significant.
doi:10.1371/journal.pone.0052326.g005
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CFTR molecules between intracellular membranal compartments
and the cell surface.
Fractionation of MP30GFP-CFTR and MP100GFP-CFTR
Populations and Distribution of GFP-CFTR between MP
Subclasses
To obtain the maximum efficiency of GFP-CFTR transfer to
target cells, it was important to determine whether a particular MP
fraction could be enriched in GFP-CFTR. To this aim, the MP30
and MP100 populations from CHO-GFP-CFTR cells were further
fractionated into subpopulations differing in density, using
ultracentrifugation in isopycnic gradients [67]. Three subpopula-
tions, corresponding to three density classes, were obtained for
each MP population (Fig. S1): (i) MPs of low density (MP30LD
and MP100LD) with a mean density (rm) of 1.10; (ii) MPs of
intermediate density (MP30ID and MP100ID; rm = 1.16); and (iii)
MPs of high density (MP30HD and MP100HD; rm = 1.21). Each
subclass of MP30 and MP100 populations was then assayed for the
presence of GFP-CFTR by flow cytometry analysis. The GFP-
CFTR protein was detected in all MP subclasses, with the highest
proportion of GFP-CFTR-positive MPs found in the high-density
compared to low-density subclasses: 14.5% for MP30HD versus
6.2% for MP30LD, and 8.3% for MP100HD versus 1.4% for
MP100LD (Table 1). This data suggested that CFTR glycoprotein
was associated with the higher density MPs.
Kinetics of MP-mediated Transfer of GFP-CFTR to Target
Cells
The following experiments were designed to determine the
capacity of each subpopulation of MPs to transfer GFP-CFTR to
target CHO cells. The MP30 (LD, ID and HD), and MP100 (LD,
ID and HD) subclasses were incubated with CHO cells at a ratio
of 5 MPs/cell for 2 h at 37uC. Inocula were removed, and
monolayers were postincubated with fresh, prewarmed medium at
37uC for 6 days. At different time-points, cell samples were
examined by fluorescence microscopy and flow cytometry for
qualitative and quantitative analyses of the GFP signal, respec-
tively. With the MP30 population, the GFP profiles did not differ
significantly for the three subclasses. At 2 h pt, 3.8 to 4.4% CHO
cells were GFP-positive, increasing to 5.5–6.6% at 4 h pt, followed
by a slight decrease at 6–8 h pt (Fig. 6A). At 8 h pt, the proportion
of GFP-positive cells increased progressively for the three MP30
subclasses, to attain a value of 73–83% GFP-positive cells 5 days pt
(Fig. 6A). A similar kinetics of appearance of GFP-positivity was
observed with the three MP100 subclasses: a discrete peak was
detected at 4 h pt, followed by a slight decrease at 6–8 h pt, and a
progressive increase to 57–76% GFP-positive cells after 5 days
(Fig. 6B).
The cell surface expression and proper membrane insertion of
GFP-CFTR was investigated by flow cytometry, using the anti-
CFTR ectodomain antibody as above. The maximal CFTR
display at the cell surface was observed at 2–3 days pt, with 50–
60% CFTR-positive cells after MP30-mediated transduction
(Fig. 7A). Similar levels (60–70% CFTR-positive cells) were
Table 1. Proportion of GFP-positive MPs in the different MP subclasses, and GFP-CFTR mRNA content (a).
Density subclass GFP(+) MP30 (% total MP) GFP(+) MP100 (% total MP) GFP-CFTR RNA in MP30(b) GFP-CFTR RNA in MP100(b)
LD (rm=1.10) 6.262.5 1.460.4 82.5614.3 97.7677.0
ID (rm= 1.16) 10.461.7 1.261.2 61.6635.2 44.0632.3
HD (rm=1.21) 14.563.2 8.362.1 51.3630.7 60.5622.5
(a)The proportion of GFP-positive MPs was determined by flow cytometry, and the GFP-CFTR mRNA content by qRT-PCR analysis. Data shown in the Table are mean
values (m) 6 SEM (n= 3).
(b)The values obtained after RT-PCR amplification of a RNA fragment of 196 nt in length overlapping the GFP C-terminal and CFTR N-terminal sequences were expressed
as ng RNA per 107 MP30 or MP100.
doi:10.1371/journal.pone.0052326.t001
Figure 6. Time-course expression of GFP-CFTR in MP-trans-
duced CHO cells. (A), (B), GFP-positive cells (expressed as %) were
determined by flow cytometry analysis of MP30-transduced (A) and
MP100-transduced cells (B), harvested at different times post-transfer
(pt). Bars represent mean values 6 SEM (n= 3).
doi:10.1371/journal.pone.0052326.g006
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observed after MP100-mediated transduction (Fig. 7B). The
presence of CFTR at the cell surface progressively declined after
day-4 (Fig. 7A, B).
Interestingly, there was a slight, but significant difference in
profile between the GFP signal and the CFTR ectodomain
immunoreactivity. The proportion of GFP-positive cells remained
as a plateau after 6 days (refer to Fig. 6 A, B) whereas the display of
CFTR at the cell surface decreased after day-4 (refer to Fig. 7).
Likewise, MP30- and MP100-recipient cells examined at day-5 pt
by confocal microscopy showed that the majority of the GFP-
CFTR signal appeared as cytoplasmic dots and speckles corre-
sponding to vesicular compartment(s), and in relatively low
proportion at the plasma membrane (Fig. S3B).
Occurrence of GFP-CFTR-encoding mRNA in MPs and
MP-recipient Cells
The kinetics of appearance of GFP-positive cells shown in Fig.5
suggested an early (4 h pt) and a late phase (3 days pt) of MP-
mediated GFP-CFTR transfer. We hypothesized that at early
times after interaction of MP30 and MP100 with target cells,
membrane-inserted GFP-CFTR glycoprotein molecules were
transferred to a small number of target cells (less than 10%),
following a pathway of MP-cell binding, endocytosis and
membrane fusion. At late times, the GFP-CFTR protein detected
in the MP-recipient cells was likely due to the neosynthesis of GFP-
CFTR from MP-embarked GFP-CFTR-encoding mRNA mole-
cules. To test this hypothesis, total RNA were extracted from the
different MP30 and MP100 subclasses, and analysed for the
presence of GFP-CFTR-encoding mRNA (mRNAgfp-cftr), using
quantitative RT-PCR and specific primers overlapping the
junction of the GFP C-terminal and CFTR N-terminal coding
sequences [55,66]. All MP subclasses were found to contain
comparable amounts of mRNAgfp-cftr (Table 1). However, when
the values of the MP content of mRNAgfp-cftr were expressed as the
ratio to b-actin mRNA content used as endogenous control,
significant differences in composition were observed between the
MP subclasses (Fig. 8A, B).
Figure 7. Time-course expression of GFP-CFTR glycoprotein at the surface of MP-transduced CHO cells. Cells harvested at different
times after MP-cell transfer were analyzed by flow cytometry for the immunoreactivity of the first N-terminal loop of the CFTR ectodomain with anti-
CFTR monoclonal antibody. (A), MP30-transduced CHO cells. (B), MP100-transduced CHO cells. Bars represent mean values 6 SEM (n=3).
doi:10.1371/journal.pone.0052326.g007
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Similarly, total RNA were extracted from MP-recipient cells
incubated with MP30 (LD, ID and HD), and MP100 (LD, ID and
HD) at day-5 pt, and qRT-PCR was carried out as above, using b-
actin mRNA as internal control. As positive controls, CHO-CD46
cells transduced by HAdV5F35-GFP-CFTR were processed for
RNA extraction and qRT-PCR assays. We found that the
recipient cells incubated with all the different subclasses of of
MP30 and MP100 contained mRNA
gfp-cftr, with a ratio to b-actin
content varying from 0.5- to 2-fold (Fig. 8C, D). Interestingly, the
variations in the cellular content of mRNAgfp-cftr reflected the
respective contents of the different MP subclasses. The observation
that almost 80% of the cells expressed GFP-CFTR protein at late
times pt suggested that nearly all cells received mRNAgfp-cftr
molecules when a bioactive MP-to-cell ratio of 5 MPs/cell was
used.
The efficiency of transfer of mRNAgfp-cftr was calculated as
follows. The average content of donor cells was found to be
4.46108 copies of mRNAgfp-cftr per mg total cellular RNA
extracted, with values ranging from 2.26108 to 6.66108 copies.
The average content of MP-recipient cells incubated with MP100-
GFP-CFTR was 3.56107 copies of mRNAgfp-cftr at 48 h after
transfer using 5 MPs/cell, with values ranging from 1.76107 to
5.36107 copies per mg total cellular RNA. We estimated the
transfer efficiency as the ratio 3.56107 : 4.46108 < 8%.
To eliminate the possibility of DNA transfer via MPs, CHO
cells were harvested at 48 h after incubation with each of the
different subclasses of MP30 and MP100, the DNA extracted and
probed for the episomal plasmid pCEP4-GFP-CFTR, using PCR
amplification of a 196 nt fragment overlapping the GFP-3’ and
CFTR-5’ sequences [66]. No specific DNA fragment was found at
this position in all cell samples tested (Fig. S4).
Functionality of Exogenous CFTR as Chloride Channel in
MP-recipient Cells
The next issue to address was whether target CHO cells
incubated with MP-GFP-CFTR acquired the CFTR-associated
chloride channel activity. CHO cells were taken 3 days after
incubation of MP30-GFP-CFTR or MP100-GFP-CFTR, the time
at which a maximum number of cells were observed to be GFP-
and CFTR-positive (refer to Fig. 6 and 7). The changes of the
DiSBAC2(3) fluorescent signal in MP-transduced cells in response
to the CFTR activator and inhibitor were monitored by
quantitative fluorescence microscopy (Fig. 9). As exemplified
with MP100-GFP-CFTR, the fluorescent signal increased progres-
sively in the presence of CFTR activators, and rapidly decreased
to background levels upon the addition of the CFTR inhibitor
GlyH-101 (Fig. 9). This effect was reversible, as the fluorescence
recovered progressively with the removal of GlyH-101 from the
Figure 8. Occurrence of GFP-CFTR-encoding mRNA in MPs and MP-transduced CHO cells. Bar graph representation of qRT-PCR assays of
MP30 (A), MP100 (B), MP30-transduced CHO cells (C), and MP100-transduced CHO cells (D). Data shown in the graphs are mean values (m) 6 SEM
(n=3). Symbols: *, p,0.05; **, p,0.01; ***, p,0.001; ns, not significant.
doi:10.1371/journal.pone.0052326.g008
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cAMP-containing superfusion medium (Fig. 9). Thus, the target
CHO cells showed a gain in biological function, i.e. the chloride
channel activity associated with acquired CFTR molecules.
Discussion
The current trends in biotherapy comprise the development of
stem cell technology in combination with ex vivo gene therapy, the
improvement of synthetic vectors, or the design of immunologi-
cally stealthy viral vectors, or safer viral integrative vectors with
controlled integration sites in host cells. The present study
explored an alternative strategy to transfer therapeutic biomole-
cules to target cells, using MPs as conveyors. MPs have been
reported to successfully mediate the transfer of surface molecules,
such as receptors and extracellular matrix proteases, and also
intracellular components, including proteins, lipids and RNA
molecules of different types [1–3,27].
In the present study, the cellular model for MP production and
uptake was the Chinese Hamster Ovarian (CHO) cell line, used as
MP-producer and MP-recipient cells. This choice was based on
the following considerations. (i) CHO cells did not express
orthologs of the human CAR, CD46 and CFTR glycoproteins,
Figure 9. CFTR channel activity in MP-transduced CHO recipient cells. (A), Evolution of the DiSBAC2(3) fluorescence signal. The time-
course analysis of DiSBAC2(3) fluorescence changes was monitored in regions of the cell monolayer corresponding to 20–30 cells, taken at 72 h post-
transfer, a time point corresponding to the maximal immunoreactivity of CFTR glycoprotein at the cell surface. Changes in the fluorescent signal were
expressed as Ft/F0 ratio values, in which Ft and F0 were the fluorescence values at the times t and t0, respectively, and t0 the time when the cAMP-
containing, CFTR-activating cocktail was added. The cocktail of CFTR activators was maintained throughout the experiment. The CFTR inhibitor GlyH-
101 was added for 5 min (phase II, marked by two vertical arrows). Phase III shows reversibility of the CFTR block and recovery of the fluorescent
signal. (B), Fluorescence microscopy. Photographs of cell monolayers were taken at different time-points corresponding to the four successive
phases, as indicated on the curve by the letters (a), (b), (c) and (d).
doi:10.1371/journal.pone.0052326.g009
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which made possible the assessment of the capability of MPs to
transfer the CAR-, CD46- and CFTR-specified function(s) to these
target cells. (ii) Previous experiments of expression of human
CFTR, CAR and CD46 in CHO cells have shown the
functionality of these proteins and their localisation at the plasma
membrane [44,48,63,68]. (iii) A homologous cell system, with the
maximal degree of compatibility between MP-donor and MP-
recipient cells in terms of membrane composition, would optimize
the cell-to-cell transfer of biological material.
Three types of human cell surface molecules with different
degrees of complexity were used as prototype bioactive glycopro-
teins in our study: (i) CAR and (ii) CD46, which are both
monospanins and act as high affinity receptors for human
adenovirus serotypes 5 and 35, respectively; and (iii) CFTR, a
complex transmembrane glycoprotein which functions as a
chloride channel. The MP-donor cells were CHO cell lines which
constitutively expressed CAR, CD46, or CFTR. MP-target cells
were naive CHO cells, which lacked CAR and CD46 and did not
express the equivalent of the human CFTR glycoprotein. In all the
three cases, the MP-donor cells were grown in the absence of
chemical or biological stress, to avoid the occurrence of apoptotic
factors within MPs and the possible transfer of stress signals to
recipient cells. The populations of MPs issued from CAR-, CD46-
or CFTR-expressing CHO cells were separated according to their
size by velocity ultracentrifugation, yielding MP30 and MP100
fractions.
We found that it was possible to transfer CAR and CD46 to
target CHO cells using MPs as vehicles, resulting in the acquisition
of new biological functions by the target cells. CHO cells
incubated with MP30CAR and MP30CD46 became permissive
to HAdV5 and AdV5F35 infection, respectively. In addition, cells
incubated with MP30CD46 acquired resistance to complement
C3-induced apoptosis. The MP-mediated transfer of CD46 might
have potential therapeutic applications in the control of allograft
rejection, as well as in gene therapy and/or vaccinology using
HAdV35-based vectors. The MP-mediated transfer of CAR might
be used to confer viral permissiveness to adenovirus-refractory
cells, such as tumor cells towards HAdV5-based oncolytic vectors.
The viral glycoprotein VSV-G, which has a high fusiogenic
activity, has been advantageously used to augment the efficacy of
membrane fusion between virus (or VLP) and target cells [35,37–
39,69–71]. In the present study however, coincorporation of VSV-
G at the surface of MP30CAR or MP30CD46 did not improve the
transfer efficiency of CAR or CD46 molecules to target cells.
In the case of CFTR, MPs were isolated from the culture
medium of CHO cells which were engineered to constitutively
express GFP-CFTR. MP30GFP-CFTR and MP100GFP-CFTR
obtained by velocity ultracentrifugation were further fractionated
into three density subclasses: MPs of low, intermediate and high
density, respectively. All MP subclasses incorporated significant
levels of GFP-CFTR protein as well as mRNAgfp-cftr, with no
significant variations between the different subclasses. Likewise, all
MP subclasses were competent in transferring GFP-CFTR to
target CHO cells. The kinetics of appearance of the GFP signal in
these cells showed two separate peaks, which suggested an early
(4–6 h) and late phase (3 days) of protein transfer after MP-cell
interaction. The early GFP signal detected in target cells likely
resulted from the transfer of GFP-CFTR protein via different
mechanisms described in the literature [1–4], such as the direct
fusion between MP membrane and target cell plasma membrane,
endocytosis of the MPs and recycling of GFP-CFTR to the cell
surface, or the coexistence of both mechanisms. Interestingly, the
incorrect insertion and orientation of a protein in the plasma
membrane of recipient cells have been reported [72]. In the
present study, the GFP-CFTR was inserted in the plasma
membrane of target cells in the correct in-out orientation, as
validated by an antibody recognising an extracellular loop of the
CFTR.
At the late phase after MP transfer, almost 80% of the target
cells became positive for GFP-CFTR, due to GFP-CFTR
molecules issued from de novo protein synthesis directed by
exogenous mRNAgfp-cftr (free or/and polysomal) transferred over
by MP30 or MP100. Attempts to block the protein synthesis
machinery in MP-recipient CHO cells using cycloheximide (CH)
were performed to further explore this mechanism. However, the
results were inconclusive, due to the unexpected high cytotoxicity
of CH towards GFP-CFTR-expressing CHO cells, when treated
with the protein synthesis inhibitory doses usually applied to
human cells (10 to 20 mg/mL; [73]). Of note, the half-life of the
CFTR gene products in human cells has been determined to be
,48 h for the CFTR glycoprotein [74,75], and $20 h for the
mRNAcftr [76].
MPs have been shown to carry and transfer mRNAs and
microRNAs to target cells, as a general mechanism of intercellular
communication [3,5,7,11,27,29]. MP-delivered RNA has been
termed shuttle RNA ( [11]), and has been found to be functional in
the new cellular context [7,29,77–80]. Consistent with the results
of these previous studies, our experimental data showed that our
shuttling mRNAgfp-cftr was functional, and that neosynthesized
GFP-CFTR glycoproteins were addressed to the cell surface of
target cells, correctly inserted into their plasma membrane, and
metabolically active in anion transport. Using a fluorescent voltage
sensitive DISBAC3(2) probe assay, the CFTR-associated chloride
channel activity was detected in MP-recipient cells at the late
phase (day-3), when the translational machinery from the
exogenous mRNAgfp-cftr became fully operational. The chloride
channel function was not detectable in MP-recipient cells at early
times, possibly due to a threshold in the detection of this activity
using the fluorescent probe.
Our observation that MP30 and MP100 produced by CHO-
GFP-CFTR donor cells were equally capable of transferring
mRNAgfp-cftr to target cells implied that both populations were
competent for CFTR delivery. Fractionation of MP30 or MP100 by
isopycnic ultracentrifugation did not result in any significant
enrichment of a particular subclass in mRNAgfp-cftr molecules.
However, in future studies using MPs issued from donor cells of
human origin, fractionation of MPs specifically carrying mRNAcftr
using MP sorting based on surface markers available in human
cells, would be advantageous for a higher efficiency of CFTR
delivery. Cell-derived MP30 or MP100 appeared therefore as
promising biological vehicles of therapeutic mRNAs exerting their
therapeutic function(s) indirectly, via their encoded proteins. In
particular, in the case of cystic fibrosis, MPs have a potential
application in nongenic, cell-to-cell autologous transfer of human
mRNAcftr and the restoration of the normal chloride channel
function in CFTR-deficient cells.
Materials and Methods
Cells and Plasmids
HEK-293 cells, obtained from the ATCC (Manassas, VA), were
maintained as monolayers in Dulbecco’s modified Eagle’s medium
(DMEM, Gibco-Invitrogen) supplemented with 10% fetal bovine
serum (FBS, Gibco-Invitrogen), penicillin (100 U/ml) and strep-
tomycin (100 mg/ml) at 37uC and 5% CO2. Chinese hamster
ovarian cells (CHO-K1 or simply CHO) was obtained from the
ATCC, CAR-expressing CHO cells (CHO-CAR) from Dr. J.
Bergelson [44], and CD46-expressing CHO cells (CHO-CD46)
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from Dr. D. Gerlier [63].They were grown in Iscove’s medium
supplemented with 10% FBS and 50 mg/ml gentamicin (Invitro-
gen). To generate the CHO cell line stably expressing GFP-
CFTR, the GFP-CFTR gene was excised from the plasmid pGFP-
CFTRwt described in a previous study [55], using Nhe I and Sma I
digestion, and inserted into pCEP4 (Invitrogen, Life Technologies).
This plasmid vector was designed for high-level, constitutive
expression from the CMV promoter, and which contains the
EBNA-1 gene for episomal maintenance in human cell lines. Sfi I-
linearized and blunted pCEP4 was further digested with Nhe I.
After purification by agarose gel electrophoresis, the Nhe I-cut
pCEP4 was ligated with the GFP-CFTR-containing Nhe I-Sma I
DNA fragment, generating the pCEP4-GFP-CFTR vector. CHO
cell monolayers were transfected with pCEP4-GFP-CFTR, using
Lipofectamine-2000 (Invitrogen), according to the manufacturer’s
instructions. CHO cells harboring pCEP4-GFP-CFTR (referred to
as CHO-GFP-CFTR) were selected using culture medium alpha-
MEM with ribonucleosides (Invitrogen), supplemented with 5%
FBS, penicillin (100 U/ml), streptomycin (100 mg/ml) and hygro-
mycin-B (50 mg/mL). The episomal plasmid pCEP4-GFP-CFTR
was found to be maintained in transfected cells for at least six
months under hygromycin-B selection pressure.
Isolation of MPs Carrying Human Glycoproteins CAR (MP-
CAR), CD46 (MP-CD46) or GFP-CFTR (MP-GFP-CFTR) (Fig.
S1)
(i) Velocity ultracentrifugation. MPs were recovered from
the culture medium of nonstressed cells, consisting of control
CHO (MP-CHO), CHO-CAR (MP-CAR), CHO-CD46 (MP-
CD46 and CHO-GFP-CFTR (MP-GFP-CFTR). This was carried
out by using a previously published centrifugation protocol [81]
with the following modifications. Cells were seeded at 70–80%
confluence, grown for 48 h to reach confluence (107 cells), then
maintained for an additional 24 h. Culture medium was clarified
from cell debris by centrifugation for 2 min at 13,0006g and 4uC.
This clarified supernatant (S0) was the source of MPs. S0 was
centrifuged at 30,0006g and 4uC for 2 h. The pellet P1 was kept,
and referred to as MP30. The supernatant (S1) was centrifuged at
100,0006g and 4uC for 2 h, to obtain pellet P2, referred to as
MP100. Pellets P1 and P2 were resuspended in 200 ml phosphate
buffered saline (PBS) with gentle mixing, for further analysis by
flow cytometry, and stored at 4uC before use for MP-mediated
protein transfer, or further MP fractionation.
(ii) Isopycnic ultracentrifugation. MP30 and MP100 were
further fractionated by ultracentrifugation of flotation in isopycnic
gradient, to separate the MP30 and MP100 fractions into subclasses
differing by their apparent density [67]. Samples of MP30 or
MP100 in PBS were placed at the bottom of a preformed linear
sucrose-D2O gradient (10 ml total volume; 0.25 to 2.5 M sucrose).
The 2.5 M sucrose solution was made in D2O buffered to pH 7.2
with NaOH, and the 0.25 M sucrose solution was made in 10 mM
Tris-HCl, pH 7.2, 150 mM NaCl, 5.7 mM Na2EDTA. The
gradients were centrifuged for 18 h at 100,0006g in a Beckman
SW41 rotor. Fractions of 0.4 ml were collected from the top, and
density measured by weighing 100 ml-aliquots, using a precision
scale. Fractions were pooled according to their apparent density,
and three pools were constituted : MPs of low density (MP30LD
and MP100LD, respectively) corresponded to pooled fractions 1–7,
with densities (r) ranging from 1.06 to 1.14 (mean r : rm = 1.10),
MPs of intermediate density (MP30ID and MP100ID) to fractions
8–14 (1.14# r #1.18; rm = 1.16), MPs of high density (MP30HD
and MP100HD) to fractions 15–21 (1.18# r #1.25; rm = 1.21).
Pooled fractions were diluted with 5 vol PBS, and MP30 pelleted
by ultracentrifugation for 2 h at 30,0006g and 4uC, and MP100
pelleted by ultracentrifugation for 2 h at 100,0006g and 4uC.
Pelleted MPs were resuspended in 200 ml PBS, further analyzed by
flow cytometry, and stored at 4uC before use in our experiments of
MP-mediated cell transfer of GFP-CFTR protein.
MP Titration
(i) Titer in total MPs. Quantification of the total MP
content in samples resuspended in PBS was determined by flow
cytometry, using a FACSCantoTM II cytometer and the DIVA6
software (Becton Dickinson Biosciences). The CountBrightTMAb-
solute Counting Beads kit (Invitrogen Catalog # C-36950) and the
Flow Cytometry Size Calibration kit (Nonfluorescent Micro-
spheres; Invitrogen Catalog # F-13838) were used for the
calibration of MP number and size, respectively. A total of
20,000 events was acquired for each sample for the calculation of
the titer in total MPs.
(ii) Titer in bioactive MPs: MP-CAR, MP-CD46 and MP-
GFP-CFTR. The proportion of MPs which displayed CAR,
CD46 or GFP-CFTR at their surface and were potential
conveyors of functional molecules was also determined by flow
cytometry, using CAR or CD46 antibodies. For MP-GFP-CFTR,
both GFP signal of the tagged CFTR protein and anti-CFTR
antibody were used for flow cytometry analysis. The titer in CAR-,
CD46 or GFP-positive MPs/ml was the one taken into account for
MP-mediated cell transduction.
MP-mediated Transfer of CAR, CD46 or GFP-CFTR into
Target Cells
Samples of CHO cell monolayers (56105 cells/well) were
incubated with 200 ml-aliquots of MP-CAR, MP-CD46 or MP-
GFP-CFTR suspensions in PBS mixed with prewarmed serum-
free medium, at a constant transducing dose of 5 MPs per cell.
After 2 h MP-cell interaction at 37uC, the 200 ml-mix was
removed and replaced by 500 ml of prewarmed complete medium.
The cells were further incubated for 48 h at 37uC, and assayed for
newly acquired functions, i.e. permissiveness to adenovirus,
resistance to complement induced apoptosis, GFP signal, or
chloride channel activity. MP-transduced cells were taken at 72 h
after MP interaction, and incubated with HAdV5-GFP or
HAdV5F35-GFP at 500 vp/cell. GFP-expression was monitored
in live cells using a Zeiss Axiovert-135 inverted microscope
(magnification:620) equipped with an AxioCam digital camera.
Cells were then harvested at 48 h pi, and GFP expression
quantitated using flow cytometry.
CD46 Anti-complement Activity
MPs isolated from the culture medium of CHO cells (negative
control MP-CHO) or CHO-CD46 (MP-CD46) were incubated
with aliquots of recipient CHO cells for 2 h at 37uC and 5% CO2,
as above described. The culture medium was then removed and
replaced by fresh medium containing complement fraction C3
(Sigma-Aldrich) at the concentrations of 1, 10, and 100 mg/mL,
and cells further incubated for 48 h. The degree of cell apoptosis
was measured by flow cytometry, using the Annexin V-FITC
apoptosis detection kit (Sigma-Aldrich) according to the manufac-
turer’s instructions.
PCR Analysis
(i) Real-time RT-PCR quantification of GFP-CFTR-
encoding mRNA. Total RNA was extracted from MPs released
from GFP-CFTR-expressing cells, or from MP-GFP-CFTR-
transduced cells, using the Nucleospin RNA II kit (Macherey
Nagel). Aliquots of 1 mg RNA was reverse transcribed using the
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SuperScriptTM III First Strand Synthesis SuperMix kit (Invitrogen)
and real-time PCR was performed using the LightCycler and a
LightCycler DNA Master SYBR Green I kit (Roche). Quantitative
real-time PCR was performed using an antisense primer designed
from the 59 end of the CFTR gene (nucleotide position 78 in the
CFTR gene; 59-GCGCTGTCTGTATCCTTTCCTCAA) and a
forward primer designed from the 39 end of the GFP gene
(nucleotide position 621; 59-AACGAGAAGCGCGATCA-
CATG). The PCR-amplified fragment was 196 nucleotides in
length and overlapped the GFP and CFTR junction sequence
[66].
(ii) GFP-CFTR DNA. The GFP-CFTR gene carried by the
pCEP4-GFP-CFTR plasmid vector was detected using the same
primers as above, on the host cell genomic DNA substrate
obtained using the DNeasy Blood and Tissue kit (Qiagen).
CFTR Channel Function Assayed by Membrane Potential-
sensitive Oxonol Probe and Cell Imaging
The fluorescent voltage sensitive probe bis(1,3-dialkylthiobarbi-
turic acid)oligomethine oxonol (DiSBAC2(3)) was used as previ-
ously described [65]. In brief, cells were loaded for 30 min with
100 nM DiSBAC2(3) in a normal chloride solution containing
136 mM NaCl, 4 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 2.5 mM
glucose and 10 mM Hepes (pH 7.4). Cells were then superfused
with DiSBAC2(3) in a low chloride solution, whereby NaCl was
replaced by sodium gluconate, and supplemented with a cAMP
cocktail consisted of 200 mM dibutyryl-adenosine 39:59-cyclic
monophosphate, 200 mM of 4-chlorophenylthio)-cAMP, 20 mM
Forskolin and 50 mM 3-isobutyl-1-methylxanthine. Fluorescent
cells were viewed on an inverted TMD300 microscope (Nikon
AG, Ku¨rsnacht, Switzerland) equipped with a high-sensitivity
black and white CoolSNAP HQ2 CCD camera (Visitron Systems
GmbH, Puchheim, Germany). DiSBAC2(3) was excited at
546 nm with a 100-W xenon lamp and the emitted fluorescence
was collected through a 580 nm barrier filter. Images were
captured every 10 sec, stored and processed using Metafluor
version 8.01 software (Universal Imaging Corp., Downington, PA).
Regions of interest were delineated for up to 30 cells and changes
in the fluorescent signal measured in each region were expressed
as the Ft/F0 ratio, in which Ft and F0 were the fluorescence values
at the time t and at the time when the cAMP cocktail was added,
respectively. The cell-permeable glycinyl hydrazone compound
(GlyH-101; Calbiochem) was used as a selective inhibitor of CFTR
at 20 mM.
Chemicals and Antibodies
Cycloheximide was purchased from Boehringer (Mannheim,
Germany). DiSBAC2(3) was purchased from Invitrogen. Mono-
clonal antibodies against VSV-G (clone P5D4), human CD46
(clone 122-2) and human CAR (clone 3C100) were purchased
from Santa Cruz Biotechnology. Polyclonal antiserum against
human, mouse, rat, bovine, equine, canine and porcine TSG101
(ref. M-19, from goat), and against human, mouse, rat, canine and
porcine CD63 (ref. H-193, from rabbit) were also purchased from
Santa Cruz Biotechnology. Alexa FluorH 568-conjugated goat
anti-mouse IgG antibody were purchased from Invitrogen. The
10-nm colloidal gold-tagged goat anti-mouse IgG antibody was
purchased from British Biocell International Ltd (Cardiff, UK).
The anti-human CFTR antibody (LS-C14758-LSBio; LifeSpan-
Biosciences, UK) was a mouse monoclonal IgM directed against
an epitope located within the first extracellular loop, spanning
amino acid residues 103–117. Alexa FluorH 568-conjugated goat
anti-mouse IgM was purchased from Invitrogen.
Viral Vectors
(i) Adenoviral vectors. HAdV5-GFP and HAdV5F35-GFP
vectors have been described in previous studies [36,55,64]. The
capsid of HAdV5F35-GFP consisted of hexon and penton base
capsomers of HAdV5, and of chimeric fibers made up of the shaft
and knob domains of serotype 35 fiber (F35) fused to HAdV5 fiber
tail. Chimeric vector HAdV5F35-GFP-CFTR has been previously
described [66]. HAdV5F35-GFP-CFTR encoded the wild-type
(wt) allele of the CFTR gene fused to the 39 end of the GFP gene.
Vector stocks were produced and titrated on HEK-293 cell
monolayers [82].
(ii) Baculoviral vector AcMNPV-VSV-G. The coding se-
quence for the glycoprotein G of vesicular stomatitis virus (VSV-
G) was inserted into the genome of Autographa californica Multi-
Capsid NucleoPolyhedrosis Virus (AcMNPV) in the polyhedrosis
gene locus, under the control of the CMV immediate-early
promoter. The infectious titer was determined by the plaque assay
method in Sf9 cells, and expressed as plaque-forming units per mL
(pfu/mL). The titer in physical virus particles of AcMPV-VSV-G
vector was determined by adsorbance measurement at 260 nm
(A260) on 1-mL samples of SDS-denatured virions (0.1% SDS for
1 min at 56uC) in 1-cm pathlength cuvette, using the following
formula : A260 of 1.0 = 0.361012 vp/mL, considering the length of
134 kbp for the viral genomic DNA. Infectious titers of stocks of
AcMPV-VSV-G concentrated by ultracentrifugation were usually
56109 to 161010 pfu/mL, and the corresponding physical particle
titers ranged between 161012 and 561012 vp/mL [36].
Electron Microscopy
(i) Negative staining of MPs. Samples were applied to
carbon-coated grid and negatively stained with 1% uranyl acetate,
pH 7.5. They were examined under a Jeol JEM-1400 electron
microscope (EM), equiped with an ORIUSTM digital camera
(Gatan France, 78113-Grandchamp).
(ii) Immunogold staining of MPs. Samples of MP suspen-
sion (10 ml) were deposited on top of carbon-coated grids. 30 sec
later, the excess of liquid was removed by blotting with filter paper.
10 ml of a 50-fold diluted solution of primary antibody (anti-CAR
or anti-CD46) was placed on the grid and incubated for 2 min at
room temperature. The antibody solution was then removed by
filter paper adsorption, and replaced by 10 ml Tris-buffered saline
(TBS). After three steps of rinsing with TBS, grids were post-
incubated with 10-nm colloidal gold-conjugated goat anti-mouse
IgG antibody (British BioCell International, Cardiff, UK; diluted
to 1:50 in TBS) for 2 min at room temperature. The secondary
antibody solution was then removed by filter paper adsorption,
and replaced by 10 ml of stain (2% uranyl acetate, pH 7.4). After a
further 1 min, the grid was dried on filter paper, and examined
under the EM as above.
(iii) EM analysis of MP-adenovirus complexes and cell
sections. Samples of MPs incubated with adenoviral vectors,
with or without postincubation with target CHO cells, were fixed
with 2% glutaraldehyde in 0.1 M sodium cacodylate buffer
(pH 7.4), pelleted, and post-fixed with osmium tetroxide (1% in
0.1 M cacodylate buffer, pH 7.4). The specimens were dehydrated
and embedded in Epon resin and sectioned. Sections were stained
with 7% uranyl acetate in methanol, post-stained with 2.6%
alkaline lead citrate in H2O, and examined under the EM as
above.
Statistics
Results were expressed as mean 6 SEM of n observations. Sets
of data were compared with an analysis of variance (ANOVA) or a
Student’s t test. Differences were considered statistically significant
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when P,0.05. Symbols used in figures were (*) for P,0.05, (**) for
P,0.01, (***) for P,0.001, and ns for no significant difference,
respectively. All statistical tests were performed using GraphPad
Prism version 4.0 for Windows (Graphpad Software).
Supporting Information
Figure S1 Schematic procedure for MP isolation and
fractionation.
(TIFF)
Figure S2 Influence of VSV-G-pseudotyping on the
efficiency on the efficiency of MP-mediated transfer of
CAR and CD46. (a), The effect of the fusiogenic VSV-G
glycoprotein on the efficiency of CAR transfer was evaluated by
the degree of CHO permissiveness to the HAdV5-GFP vector.
Aliquots of CHO cells were incubated with MP30CAR at different
MP doses per cell, as indicated in the x-axis. At 72 h after
MP30CAR interaction, cells were infected with HAdV5-GFP
vector. Adenoviral vector HAdV5F35-GFP, which does not
recognize CAR as cellular receptor, was used as the negative
control. (b), The effect of VSV-G on the efficiency of CD46
transfer was evaluated by the degree of CHO permissiveness to the
HAdV5F35-GFP vector. Aliquots of CHO cells were incubated
with MP30CD46 at different MP doses per cell, as indicated in the
x-axis. At 72 h after MP30CD46 interaction, cells were infected
with HAdV5F35-GFP vector. Adenoviral vector HAdV5-GFP,
which does not recognize CD46 as cellular receptor, was used as
the negative control. In (a) and (b), MP30 lacking CAR or CD46
and carrying VSV-G alone were used as negative controls for
CAR and CD46 receptor activity, respectively.
(EPS)
Figure S3 Cellular localization of GFP-tagged CFTR
glycoprotein in MP-donor and MP-recipient CHO cells.
(A), MP-donor cells. CHO cells expressing the GFP-CFTR
fusion glycoprotein from the pCEP4-GFP-CFTR episomal plas-
mid were examined in confocal fluorescence microscopy. (B),
MP-recipient CHO cells. CHO cells harvested at day-5 after
interaction with MP30-GFP-CFTR were examined as above. (a),
Cell observed in the GFP channel. (b), Merging of image (a) and
DAPI staining. Scale bar, 10 mm.
(TIFF)
Figure S4 DNA analysis of MP-GFP-CFTR-recipient
cells. CHO cells were harvested at day-5 after interaction with
the following MP subclasses: MP30-LD (lane 1), MP30-ID (lane 2),
MP30-HD (lane 3), MP100-LD (lane 4), MP100-ID (lane 25),
MP100-HD (lane 6). DNA was extracted and analysed by PCR for
the possible occurrence of pCEP4-GFP-CFTR, visualized by a
specific 196-nt fragment. DNA from CHO-CD46 infected with
Ad5F35-GFP-CFTR was used as positive control (lane 7). Lane 8,
1kb-DNA ladder (Fermentas).
(TIFF)
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